Previous 10 | Next 10 |
Investment Thesis The investment thesis of this article is that a most important reason for investing in any stock is its potential for portfolio wealth-building, and that requires informed forecasts of its likely future price. Abiomed Inc. ( ABMD ) now scores less than at other times for ...
Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI , which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best ...
Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief medical officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202006150051...
Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, whi...
Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the William Blair 40 th Annual Growth Stock Conference (virtual) on Wednesday,...
Compugen Received FDA Clearance of IND Application Compugen ( CGEN ) announced that the FDA has given its clearance for the Investigational New Drug for Phase 1/2 study of its Triple combination therapy for cancer. The company expects to initiate the trial during the second half of the yea...
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP....
Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:00...
2020 has been a crazy year for investors. The Dow Jones Industrial Average , S&P 500 , and Nasdaq all started the year strong, with the three major U.S. indexes trading at all-time highs in February. Image source: Getty Images. Continue reading
Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it will host a Virtual Investor Day covering Clinical Data & Innovation on May 27, 2020 from 8:30 a.m. – 12:00 p.m. EDT. The event will include presentations from memb...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...